Anti-Hypertensive Drugs - Croatia

Croatia

The Anti-Hypertensive Drugs market in Croatia is expected to witness a significant growth in the coming years.
According to projections, the revenue in this market is set to reach US$7.76m by 2024.
Furthermore, it is anticipated that the market will exhibit a Compound Annual Growth Rate (CAGR) of -0.47% from 2024 to 2029, resulting in a market volume of US$7.58m by the end of the forecast period.
In comparison to other countries, United States is expected to dominate the global market, generating the highest revenue of US$12,290.00m in 2024.
In Croatia, the demand for locally produced anti-hypertensive drugs has been steadily increasing due to growing concerns about import dependence.

Key regions: Japan, India, Italy, Brazil, South Korea

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Hypertensive Drugs market in Croatia is experiencing significant growth in recent years.

Customer preferences: Croatia has a high prevalence of hypertension, which is driving the demand for anti-hypertensive drugs. The aging population is also contributing to the growth of the market, as hypertension is more common in older adults. Patients in Croatia prefer combination drugs that offer convenience and ease of use, rather than taking multiple medications.

Trends in the market: The Anti-Hypertensive Drugs market in Croatia is witnessing a shift towards generic drugs due to their affordability. The government's cost containment measures and the increasing availability of generic drugs are driving this trend. The market is also witnessing an increase in the use of fixed-dose combination drugs, which offer improved efficacy and compliance.

Local special circumstances: Croatia has a universal healthcare system that provides access to affordable medication. The government has implemented policies to promote the use of generic drugs, which has led to increased competition in the market. The country has a well-established pharmaceutical industry, which is contributing to the growth of the market.

Underlying macroeconomic factors: Croatia's economy has been growing steadily in recent years, which has led to an increase in healthcare spending. The government is investing in healthcare infrastructure and services, which is driving the growth of the pharmaceutical industry. The aging population and the high prevalence of hypertension are also contributing to the growth of the Anti-Hypertensive Drugs market in Croatia.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.